Evidence map›Paper›PMID 31705056›Full record

ArticleScientific reports2019

Efficiency score from data envelopment analysis can predict the future onset of hypertension and dyslipidemia: A cohort study.

Sho Nakamura, Hiroto Narimatsu, Yoshinori Nakata, Masahiko Sakaguchi, Tsuneo Konta, Masafumi Watanabe, Yoshiyuki Ueno, Kenichi Ishizawa, Hidetoshi Yamashita, Takamasa Kayama and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Is the Efficiency Score an Indicator for Incident Hypertension in the Community Population of Western China?International journal of environmental research and public health · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sho NakamuraDepartment of Clinical Oncology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan. sho-nakamura@umin.org.ORCID http://orcid.org/0000-0002-5378-9477
Hiroto NarimatsuSchool of Health of Innovation, Kanagawa University of Human Services, 3-25-10 Research Gate Building 2-A, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-0821, Japan.ORCID http://orcid.org/0000-0002-0383-4911
Yoshinori NakataDepartment of Healthcare Management, Teikyo University Graduate School of Public Health, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Masahiko SakaguchiCancer Prevention and Control Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan.
Tsuneo KontaDeparment of Public Health, Yamagata University Graduate School of Medicine, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan.
Masafumi WatanabeDepartment of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan.
Yoshiyuki UenoDepartment of Gastroenterology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan.ORCID http://orcid.org/0000-0001-5623-4250
Kenichi IshizawaDepartment of Neurology, Hematology, Metabolism, Endocrinology and Diabetology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan.
Hidetoshi YamashitaDepartment of Ophthalmology and Visual Sciences, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan.
Takamasa KayamaGlobal Center of Excellence, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan.
Takashi YoshiokaDepartment of Clinical Oncology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Yamagata, 990-9585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary prevention focuses on ensuring that healthy people remain healthy. As it is practically difficult to provide intervention for an entire healthy population, it is essential to identify and target the at risk of risks population. We aimed to distinguish at risk of risks population using data envelopment analysis (DEA). Efficiency score was calculated from the DEA using a cohort sample and its association with the onset of hypertension and dyslipidemia was analyzed. A stratification analysis was performed according to the number of conventional risk factors in participants. The adjusted odds ratios (aORs) of the incidence of hypertension and dyslipidemia according to a 0.1-point increase in efficiency score were 0.66 (90% confidence interval [CI] 0.55-0.78, p < 0.0001) and 0.84 (90% CI 0.75-0.94, p = 0.01), respectively. In the stratification analysis, aOR of the incidence of hypertension according to a 0.1-point increase in efficiency score was 0.57 (90% CI 0.37-0.89, p = 0.04) in participants with no conventional risk factors. Participants with lower efficiency score were suggested to be at high risk for future onset of hypertension and dyslipidemia. The DEA might enable us to identify the risk of hypertension where conventional methods might fail.

Indexed as

Computational BiologyCohort StudiesDyslipidemiasHumansHypertensionLife StyleLogistic ModelsOdds RatioPrognosisRisk Assessment

Identifiers

PMID31705056
PMCPMC6841950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.